Compare a current INR with common target ranges and review rough weekly-dose math, interaction context, and tablet-strength reference information for warfarin follow-up discussions.
This warfarin worksheet compares a current INR with the target range used for the selected indication and shows the kind of weekly-dose arithmetic many anticoagulation services review when a result is slightly below or above range. It is meant for dose-review conversations and cross-checking, not for self-adjusting anticoagulation at home.
Warfarin has a narrow therapeutic window, and dose requirements vary widely between patients. Age, liver function, diet, acute illness, missed doses, and interacting medicines can all shift the INR. Genetic factors such as CYP2C9 and VKORC1 also help explain why two patients with the same indication may need very different weekly totals.
Because of that variability, the useful question is usually not "What is the right milligram number?" but "How far from range is the INR, what changed recently, and is simple weekly-dose math still reasonable?" This page keeps the target range, weekly total, interaction list, and tablet strengths in one place so the calculation can be reviewed in context.
Warfarin follow-up usually hinges on the weekly total, the target range, recent interacting changes, and whether the result is only slightly out of range or clearly concerning. Keeping those pieces together makes it easier to review the math without pretending the page can replace an anticoagulation service or clinician.
Common worksheet ranges shown on this page: Below range: many clinics review a weekly increase of roughly 5–20% Slightly above range: many clinics review a weekly decrease of roughly 5–10% More clearly above range but < 5: many clinics review roughly 10–15% reductions When INR is > 5, this page stops short of routine weekly-dose math and shifts to review-context wording because individual management depends on bleeding status, recent changes, and local anticoagulation pathways.
Result: Below Range; common worksheet review: about 38.5 mg/week (5.5 mg/day) with a nearest tablet strength of 5 mg
A patient taking 5 mg daily (35 mg/week) for atrial fibrillation with an INR of 1.5 is below the common 2.0–3.0 target range. A typical worksheet starting point is roughly a 10% weekly increase, which moves the total to about 38.5 mg/week. That number is only cross-check arithmetic; real follow-up still depends on missed doses, recent medication or diet changes, and bleeding/clotting context.
Warfarin dose requirements can vary several-fold between patients. CYP2C9 affects metabolism, VKORC1 affects sensitivity, and everyday clinical issues such as illness, liver function, alcohol intake, missed doses, and changing vitamin K intake often matter just as much in routine follow-up. That is why a patient with the same indication and a similar INR may still need a very different long-term weekly dose than someone else.
Most review workflows think in total weekly milligrams rather than one tablet strength per day. Weekly totals allow smaller adjustments by alternating strengths across the week, which is often more realistic than trying to force every day to look identical. This page therefore keeps the weekly total, daily average, and nearest tablet strength in the same place.
Small INR deviations often invite rough percentage math, but that approach weakens once the INR is markedly elevated or the patient has bleeding symptoms, major interacting changes, or peri-procedural considerations. In those settings, the more important question is not the next arithmetic step but whether the overall situation still fits routine outpatient follow-up or needs more urgent individualized review.
Last updated:
This worksheet compares a current INR with common target ranges and shows rough weekly-dose review math. It is a dose-review aid, not a self-adjustment plan.
Atrial fibrillation is commonly managed to an INR range of 2.0–3.0. That range is used as the reference context on this page, but the treating clinician or anticoagulation service should confirm the actual goal for a specific patient.
Follow-up timing depends on how stable the INR has been, whether a dose change was made, and whether a new interaction or illness is in play. Stable long-term patients may be reviewed at wider intervals, while out-of-range results often prompt much sooner follow-up.
Foods rich in vitamin K can lower the INR if intake changes meaningfully from the usual pattern. The practical issue is consistency: large swings in vitamin K intake make INR interpretation harder than a steady diet does.
Once the INR is markedly elevated, the safe next step depends on more than percentage math. Bleeding symptoms, recent medication changes, liver function, falls, procedures, and local anticoagulation pathways matter, so the page shifts to review-context wording instead of pretending a single weekly number is enough.
They are usually close enough for most patients, but any manufacturer change is still worth noting when an INR trend stops making sense. A review after the switch is more useful than assuming the product change could never matter.
Direct oral anticoagulants such as apixaban, rivaroxaban, dabigatran, and edoxaban generally do not require INR monitoring and have fewer food interactions. Warfarin still remains relevant for some mechanical valves, certain thrombophilia scenarios, and settings where cost or other factors matter.